Intrinsic Therapeutics Inc.

Intrinsic Therapeutics Inc. manufactures Barricaid, a bone-anchored implant device designed to reduce the incidence of reherniation and reoperation in patients with large annular defects following lumbar discectomy. The Barricaid implant is FDA-approved and represents the first device clinically proven to prevent recurrent disc herniation in high-risk patients. The company has spent over two decades developing this solution in collaboration with world-renowned surgeons, scientists, and clinical investigators. Barricaid is indicated for patients undergoing lumbar discectomy who have large annular defects and elevated reherniation risk. The device is positioned to optimize surgical outcomes and reduce associated pain and disability from recurrent lumbar disc herniation. The company markets Barricaid to both physicians and patients, emphasizing clinical evidence demonstrating significantly reduced disc reherniations and reoperation rates compared to standard discectomy alone.